With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.61363-56-2,2H-Pyran-3,5(4H,6H)-dione,as a common compound, the synthetic route is as follows.
61363-56-2, EXAMPLE 34 5-(2,1,3-benzoxadiazol-5-yl)-5,10-dihydro-1H,3H-dipyrano[3,4-b:4, 3-e]pyridine-4,6(7H,9H)-dione A mixture of tetrahydropyran-3,5-dione (Terasawa, J. Org. Chem. (1977), 42, 1163-1169) (0.27 g, 2.4 mmol), 2,1,3-benzoxadiazole-5-carboxaldehyde (Gasco, A. M. Eur.J.Med.Chem.Chim.Ther. (1996), 31,3-10) (0.54 g, 2.9 mmol) and the product from Example 11C (0.27 g, 2.4 mmol) in ethanol (3 mL) was processed as described in Example 29 to provide the title compound (0.088) as a solid. mp>260 C.; MS (ESI(-)) m/z 338 (M-H)31; H NMR (DMSO-d6) delta 4.08 (s, 4H), 4.54 (AB q, 4H), 5.06 (s, 1H), 7.61 (m, 2H), 7.97 (d, 1H), 10.23 (bs, 1H); Anal. Calcd for C17H13N3O50.5 C2H6O: C, 59.15; H, 4.26; N,11.83. Found: C, 59.09;H, 4.32; N, 11.99.
As the paragraph descriping shows that 61363-56-2 is playing an increasingly important role.
Reference£º
Patent; Abbott Laboratories; US6642222; (2003); B2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics